logo
Twitter
Discord
Email
logo
ResMed Inc.

ResMed Inc.

NYSE•RMD
CEO: Mr. Michael J. Farrell BE, MBA, SM
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1995-06-02
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Contact Information
9001 Spectrum Center Boulevard, San Diego, CA, 92123, United States
858-836-5000
www.resmed.com
Market Cap
$37.79B
P/E (TTM)
26.3
28.2
Dividend Yield
0.9%
52W High
$293.81
52W Low
$199.92
52W Range
62%
Rank16Top 3.7%
6.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$1.34B+9.07%
4-Quarter Trend

EPS

$2.38+12.26%
4-Quarter Trend

FCF

$414.36M+35.44%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Total Revenue Increased 9% Net revenue reached $1.34B USD for the quarter, marking a 9% increase over prior year period.
Gross Margin Significantly Improved Gross margin expanded to 61.5% from 58.6%, driven by manufacturing and logistics efficiencies realized.
Diluted EPS Grew 12% Diluted EPS was $2.37 USD, reflecting a strong 12% increase compared to the prior year period results.
Strong Cash Flow Generation Net cash provided by operating activities totaled $457.3M USD, showing a $131.8M increase from last year.

Risk Factors

Workforce Restructuring Charges Recorded $15.8M USD in restructuring charges during the quarter for employee severance and planning activities.
Ongoing Patent Litigation Exposure Facing multiple patent infringement suits, including pending appeals, creating uncertainty regarding final outcomes.
Inflationary Cost Pressures Sustained inflation may adversely affect gross margin if higher costs cannot be fully offset by price increases.
New Accounting Standard Adoption Currently evaluating impact of recently issued ASU 2025-06 regarding internal-use software accounting framework.

Outlook

Continued R&D Investment Focus Invested $87.3M USD in R&D, representing 6.5% of net revenues, focusing on product enhancements.
Residential Care Software Growth Expecting continued growth in Residential Care Software, driven by strong performance in the MEDIFOX DAN vertical.
Strong Liquidity Position Total cash and available liquidity stands at $2.88B USD, sufficient for next twelve months operations.
Share Repurchase Program Active Repurchased $150.0M USD of treasury stock during the quarter; $10.3M shares remain available.

Peer Comparison

Revenue (TTM)

Cardinal Health, Inc.CAH
$234.31B
+4.5%
Humana Inc.HUM
$126.36B
+9.9%
Takeda Pharmaceutical Company LimitedTAK
$29.67B
-2.8%

Gross Margin (Latest Quarter)

Humana Inc.HUM
100.0%
+0.0pp
Edwards Lifesciences CorporationEW
77.9%
-2.7pp
Takeda Pharmaceutical Company LimitedTAK
65.8%
-0.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BDX$58.32B34.66.6%34.7%
TAK$51.27B241.60.5%32.1%
EW$48.74B35.613.4%5.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.4%
Moderate Growth
4Q Net Income CAGR
0.4%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Jan 29, 2026
|
EPS:$2.68
|
Revenue:$1.40B
Reports
All Years
  • Form 10-Q - Q1 2026

    Period End: Sep 30, 2025|Filed: Oct 31, 2025|
    Revenue: $1.34B+9.1%
    |
    EPS: $2.38+12.3%
    Miss
  • Form 10-K - FY 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $5.15B+9.8%
    |
    EPS: $9.55+37.6%
    Beat
  • Form 10-Q - Q3 2025

    Period End: Mar 31, 2025|Filed: Apr 24, 2025|
    Revenue: $1.29B+7.9%
    |
    EPS: $2.49+22.1%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Dec 31, 2024|Filed: Jan 31, 2025|
    Revenue: $1.28B+10.3%
    |
    EPS: $2.35+65.5%
    Meet
  • Form 10-Q - Q1 2025

    Period End: Sep 30, 2024|Filed: Oct 25, 2024|
    Revenue: $1.22B+11.1%
    |
    EPS: $2.12+42.3%
    Beat
  • Form 10-K - FY 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $4.69B+10.9%
    |
    EPS: $6.94+13.4%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Mar 31, 2024|Filed: Apr 26, 2024|
    Revenue: $1.20B+7.2%
    |
    EPS: $2.04+29.1%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Dec 31, 2023|Filed: Jan 25, 2024|
    Revenue: $1.16B+12.5%
    |
    EPS: $1.42-7.2%
    Miss